It has been reported that the aggregates of ubiquitin-conjugated protein (aggresome) formation block bortezomib-induced apoptosis in pancreatic cancer cells, and inhibition of the formation of the aggresome by the HDAC inhibitor can strongly potentiate the efficacy of bortezomib35. This evidence concerns the gene HDAC9 and pancreatic neoplasm.